EUCTR2008-005779-86-FR进行中（未招募）1 期
A Pilot study to evaluate the Efficacy and Safety of GFT505 (80 mg) orally administered once daily for 28 days in atherogenic dyslipidaemic patients with abdominal obesity. A double blind, placebo-controlled and randomized study.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- GENFIT
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must meet all of the following inclusion criteria to be eligible for enrolment into the trial:
- •1) Provide written informed consent prior to enrolment.
- •2) Male or post-menopausal female (defined as >12 months since last menstrual period and with stable (at least 6 months prior to screening) and continuous Hormonal Replacement Therapy if any- surgical removal of ovaries can be considered as surgical menopause”)).
- •3) Aged from 18 to 75 years.
- •4) Waist circumference =102cm for male, = 88cm for female.
- •5) Atherogenic dislipidaemia* inadequately controlled despite Therapeutic Lifestyle Change (TLC) recommendations (diet and exercise). * (documented or highly probable at V1)
- •6) Patients without previous experience of CVD**.
- •** Cardiovascular disease will be defined as:
- •1) Peripheral Artery Disease
- •a) Lower limb [history of acute leg ischemia or clinical symptoms of arteriopathy (intermittent claudication)]
- •b) Peripheral carotid artery disease [history of stroke, TIA (Transient Ischemic Attack)]
- •c) Abdominal aortic aneurysm
- •2) Coronary Heart Disease (Angina pectoris, history of myocardial infarction, revascularisation procedures)
- •7) Non-hypertensive or patient taking antihypertensive medication (except non-permitted medication) maintained at a stable dose for 2 months at least prior to screening (and the stable dose can be maintained throughout the study).
- •In addition to the above criteria, all of the following inclusion criteria must be fulfillled at V2 (or results of V2 labs):
- •8) 150= fasting TG = 600 mg/dL (1.69 = fasting TG = 6.78 mmol/L) at V2
- •9) Fasting HDL-C = 40 mg/dL (= 1.03 mmol/L) for male, HDL-C = 45 mg/dL (= 1.16 mmol/L) for female at V2
- •In addition to the above criteria, the following inclusion criterion must be fulfillled at V3:
- •10) Patient agrees to come to following visits and it is possible to schedule V4 and V5 inside the protocol specified range (14 days +/- 2 days between V3 and V4; 14 days +/- 2 days between V4 and V5).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Body Mass Index (BMI) = 40 kg/m².
- •2) Weight change (variation >5%) within 6 months at least prior to screening.
- •3) Known Heart Failure (Grade I to IV of NYHA classification).
- •4) Blood Pressure > 160 / 95 mmHg.
- •5) Known alcohol and/or any other drug abuse or dependence. Alcohol consumption of more than 3 alcoholic beverages per day is considered abusive. One alcoholic beverage is defined as 30 mL distilled spirits, 120 mL wine, or 330 mL beer.
- •6) Type I or type II Diabetes Mellitus.
- •7) Evidence of any other unstable or untreated clinically significant immunological, neoplastic, endocrine, haematological, gastrointestinal, neurological or psychiatric abnormalities or medical disease.
- •8) Known homozygous familial hypercholesterolaemia or known Type III hyperlipoproteinaemia (familial dysbetalipoproteinaemia).
- •9) Patients who have serious or unstable medical or psychological conditions which, in the opinion of the Investigator, would lead the patient to be non-compliant or uncooperative during the study or would compromise the patient’s safety or successful participation in the study
- •10) Patients who have donated blood or blood products within the previous month prior to screening or who plan to donate blood or blood products at any time during the trial and in the 3 months following the end of the study
- •11) The Patient is a female of childbearing potential, is pregnant or lactating
- •12) Any medication that may interfere with study medication absorption, distribution, metabolism or excretion or could lead to induction or inhibition of microsomial enzymes within 3 months prior to the screening day.
- •13) Currently taking other investigational drugs or who have taken part in a clinical trial within the previous month prior to screening.
- •14) Known intolerance or contra-indication to the list of excipients of GFT505 (Gelatin, Lactose monohydrate, Titanium dioxide, Red Iron Oxide, Magnesium Stearate).
- •15) Patient not covered by Health Insurance System and/or not in compliance with the recommendations of National Law in force.
- •16) Patient who cannot be contacted in case of emergency.
- •In addition to the above criteria, the patient should not present any of the following exclusion criteria at V2 (or results of V2 labs):
- •17) Uncontrolled hypothyroidism defined as TSH > 2 x the upper limit of normal (ULN) at V2 (thyroid dysfunction controlled for at least 6 months prior to screening is permitted).
- •18) Significant renal disease, including nephritic syndrome, chronic renal failure (defined as creatinine clearance < 60 mL/mn according to Cockroft-Gault formula and serum creatinine >180 µmol/L at V2).
- •19) Active liver disease or hepatic dysfunction***** as defined by elevations in liver enzymes: [alanine aminotransferase (ALT), aspartate aminotransferase (AST)] >3 x the upper limit of normal (ULN) at V2, or [gamma glutamyltransferase (GGT) and alkaline phosphatases (ALP)] > 2 x the upper limit of normal (ULN) at V2.
- •***** Patients with NonAlcoholic SteatoHepatitis (NASH) will be allowed to participate in the study.
- •20) Unexplained serum creatine phosphokinase (CPK) > 3 x the upper limit of normal (ULN) at V2. Patients with a reason for CPK elevation may continue in screening and have the measurement repeated prior to randomization; a repeat CPK > 3 x ULN is exclusionary.
- •In addition to the above criteria, the patient should not present any of the following exclusion criteria at V3:
- •21) Patient for whom the wash-out period of lipid-regulating drugs (f
研究者
相似试验
进行中（未招募）
1 期
A Pilot study to evaluate the Efficacy and Safety of GFT505 orally administered once daily (30 mg) for 28 days in atherogenic dyslipidaemic patients with abdominal obesity. A double blind, placebo-controlled and randomized study.EUCTR2007-004337-41-FRGENFIT30
进行中（未招募）
1 期
A Pilot study to evaluate the Efficacy and Safety of GFT505 (80mg) orally administered once daily for 35 days in patients presenting with impaired glucose tolerance and abdominal obesity. A double blind, parallel group, placebo-controlled and randomized study.patients presenting with impaired glucose tolerance and abdominal obesityMedDRA version: 9.1Level: LLTClassification code 10036481Term: Pre-diabetesMedDRA version: 9.1Level: LLTClassification code 10059179Term: Abdominal obesityEUCTR2009-011003-23-FRGENFIT40
进行中（未招募）
1 期
A Pilot study to evaluate the Efficacy and Safety of GFT505 (30 mg) orally administered for 28 days in patients with Frederickson Type IIb Dyslipidemia (Mixed Hyperlipidemia). A double blind, placebo-controlled and randomized study.EUCTR2007-003237-16-FRGENFIT30
进行中（未招募）
不适用
A Pilot study to evaluate the Efficacy and Safety of GFT505 (80mg) orally administered once daily for 12 weeks in patients with Type 2 Diabetes mellitus.A Multicentre, Randomised, Double Blind, Placebo-Controlled study.EUCTR2010-021986-60-LVGENFIT120
尚未招募
不适用
A Pilot study to Evaluate the Efficacy and Safety of Autologous Adipose tissue-derived Stromal Vascular Fraction(SVF) treatment for the Patients with articular cartilage injury of the kneeKCT0005566Samsung Medical Center3